Loading organizations...
§ Private Profile · Strasbourg, Alsace, France
Preclinical biotech developing first-in-class small molecule drugs targeting the ER stress pathway for aggressive cancers.
Based in Strasbourg, France, BiPER Therapeutics is a preclinical-stage biotechnology company developing first-in-class small molecule drugs that target the endoplasmic reticulum stress pathway to treat aggressive and drug-resistant cancers. The organization focuses on selectively inhibiting the BiP protein to induce tumor cell death, advancing its lead candidate, BPR001-615, toward clinical trials for gastrointestinal oncology. Operating with a current team of seven employees, the startup has secured a total of €2.05 million in financing, including a €1.25 million seed round and a recent €800,000 bridge funding tranche in December 2024. The company's research and financial backing involve strategic partnerships with recognizable entities such as lead investor AdBio partners, public financial supporter Bpifrance, and the French national research institute Inserm. BiPER Therapeutics was founded in 2021 by Mehdi Chelbi, Rachid Benhida, Stéphane Rocchi, and Cyril Ronco.
BiPER Therapeutics has raised $2.5M across 2 funding rounds.
BiPER Therapeutics has raised $2.5M in total across 2 funding rounds.
BiPER Therapeutics has raised $2.5M across 2 funding rounds. Most recently, it raised $1.2M Other Equity in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 2, 2025 | $1.2M Venture Round | Noomane Fehri | Bpifrance | Announced |
| Feb 14, 2023 | $1.3M Grant | — | Bpifrance, Grand EST Region, Wiseed | Announced |
BiPER Therapeutics has raised $2.5M in total across 2 funding rounds.
BiPER Therapeutics's investors include Noomane Fehri, Bpifrance, Grand-Est Region, WiSEED.